The effects of anti-inflammatory drug treatment in gastric cancer prevention: An update of a metaanalysis

Journal of Cancer

Volumn 7, Issue 15, 2016, Pages 2247-2257

  Kong, Pengfei ^a   Wu, Ruiyan ^a   Liu, Xuechao ^a   Liu, Jianjun ^a   Chen, Shangxiang ^a   Ye, Minting ^a   Yang, Chenlu ^a   Song, Ze ^a   He, Wenzhuo ^a   Yin, Chenxi ^a   Yang, Qiong ^a   Jiang, Chang ^a   Liao, Fangxin ^a   Peng, Roujun ^a   Zhou, Zhiwei ^a   Xu, Dazhi ^a   Xia, Liangping ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Anti inflammatory drug; Gastric cancer; Meta analysis; Prevention; Risk factor

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; DOSE RESPONSE; DRUG EFFECT; GEOGRAPHY; HUMAN; LOW DRUG DOSE; META ANALYSIS; RISK REDUCTION; STOMACH CANCER; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 85007099122     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.16524     Document Type: Article

References (74)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015; 65: 87-108.
2. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009; 374: 477-90.
3. Wang D, Dubois RN. Prostaglandins and cancer. Gut. 2006; 55: 115-22.
4. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Annals of internal medicine. 1994; 121: 241-6.
5. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. Journal of the National Cancer Institute. 2002; 94: 252-66.
6. Shaheen NJ, Straus WL, Sandler RS. Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs. Cancer. 2002; 94: 950-63.
7. Leung KH, Mihich E. Prostaglandin modulation of development of cellmediated immunity in culture. Nature. 1980; 288: 597-600.
8. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Annals of clinical and laboratory science. 2000; 30: 3-21.
9. Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M, et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer research. 2005; 65: 6275-81.
10. Gillies M, Skyring A. Gastric ulcer, duodenal ulcer and gastric carcinoma: a case-control study of certain social and environmental factors. The Medical journal of Australia. 1968; 2: 1132-6.
11. Akre K, Ekstrom AM, Signorello LB, Hansson LE, Nyren O. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. British journal of cancer. 2001; 84: 965-8.
12. Duan L, Wu AH, Sullivan-Halley J, Bernstein L. Nonsteroidal antiinflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008; 17: 126-34.
13. Epplein M, Nomura AM, Wilkens LR, Henderson BE, Kolonel LN. Nonsteroidal antiinflammatory drugs and risk of gastric adenocarcinoma: the multiethnic cohort study. American journal of epidemiology. 2009; 170: 507-14.
14. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1998; 7: 97-102.
15. Gammon MD, Terry MB, Arber N, Chow WH, Risch HA, Vaughan TL, et al. Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2004; 13: 34-9.
16. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. Journal of the National Cancer Institute. 2003; 95: 1784-91.
17. Tian W, Zhao Y, Liu S, Li X. Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation. 2010; 19: 288-98.
18. Ye X, Fu J, Yang Y, Gao Y, Liu L, Chen S. Frequency-risk and duration-risk relationships between aspirin use and gastric cancer: a systematic review and meta-analysis. PloS one. 2013; 8: e71522.
19. Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. British journal of cancer. 2003; 88: 684-8.
20. Yang P, Zhou Y, Chen B, Wan HW, Jia GQ, Bai HL, et al. Aspirin use and the risk of gastric cancer: a meta-analysis. Digestive diseases and sciences. 2010; 55: 1533-9.
21. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Lowdose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. Jama. 2005; 294: 47-55.
22. Ajdarkosh H, Sohrabi M, Moradniani M, Rakhshani N, Sotodeh M, Hemmasi G, et al. Prevalence of gastric precancerous lesions among chronic dyspeptic patients and related common risk factors. European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation. 2015; 24: 400-6.
23. Gong EJ, Ahn JY, Jung HY, Lim H, Choi KS, Lee JH, et al. Risk factors and clinical outcomes of gastric cancer identified by screening endoscopy: a casecontrol study. Journal of gastroenterology and hepatology. 2014; 29: 301-9.
24. Jung S, Park CH, Kim EH, Shin SJ, Chung H, Lee H, et al. Preventing metachronous gastric lesions after endoscopic submucosal dissection through Helicobacter pylori eradication. Journal of gastroenterology and hepatology. 2015; 30: 75-81.
25. Sheu BS, Tsai YC, Wu CT, Chang WL, Cheng HC, Yang HB. Long-term celecoxib can prevent the progression of persistent gastric intestinal metaplasia After H. pylori eradication. Helicobacter. 2013; 18: 117-23.
26. Steevens J, Schouten LJ, Goldbohm RA, van den Brandt PA. Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study. Gut. 2010; 59: 39-48.
27. Wong BC, Zhang L, Ma JL, Pan KF, Li JY, Shen L, et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut. 2012; 61: 812-8.
28. Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28: 2952-7.
29. Wu Y, Fan Y, Jiang Y, Wang Y, Liu H, Wei M. Analysis of risk factors associated with precancerous lesion of gastric cancer in patients from eastern China: a comparative study. Journal of cancer research and therapeutics. 2013; 9: 205-9.
30. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology. 2010; 25: 603-5.
31. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Statistics in medicine. 1988; 7: 889-94.
32. Kong P, Cai Q, Geng Q, Wang J, Lan Y, Zhan Y, et al. Vitamin intake reduce the risk of gastric cancer: meta-analysis and systematic review of randomized and observational studies. PloS one. 2014; 9: e116060.
33. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. Journal of chronic diseases. 1978; 31: 691-6.
34. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis. Journal of the National Cancer Institute. 1993; 85: 307-11.
35. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW, Jr. Aspirin use and risk of fatal cancer. Cancer research. 1993; 53: 1322-7.
36. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994; 5: 138-46.
37. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis and rheumatism. 1997; 40: 1580-6.
38. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet. 1998; 351: 233-41.
39. Awan A, Johnston DE, Jamal MM. Gastric outlet obstruction with benign endoscopic biopsy should be further explored for malignancy. Gastrointestinal endoscopy. 1998; 48: 497-500.
40. Zaridze D, Borisova E, Maximovitch D, Chkhikvadze V. Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. International journal of cancer Journal international du cancer. 1999; 82: 473-6.
41. Suleiman UL, Harrison M, Britton A, McPherson K, Bates T. H2-receptor antagonists may increase the risk of cardio-oesophageal adenocarcinoma: a case-control study. European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation. 2000; 9: 185-91.
42. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of antiinflammatory drugs on overall risk of common cancer: case-control study in general practice research database. Bmj. 2000; 320: 1642-6.
43. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2000; 9: 119-23.
44. Fischbach LA, Correa P, Ramirez H, Realpe JL, Collazos T, Ruiz B, et al. Antiinflammatory and tissue-protectant drug effects: results from a randomized placebo-controlled trial of gastritis patients at high risk for gastric cancer. Alimentary pharmacology & therapeutics. 2001; 15: 831-41.
45. Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. British journal of cancer. 2003; 88: 1687-92.
46. Nomura AM, Hankin JH, Kolonel LN, Wilkens LR, Goodman MT, Stemmermann GN. Case-control study of diet and other risk factors for gastric cancer in Hawaii (United States). Cancer causes & control: CCC. 2003; 14: 547-58.
47. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer research. 2004; 24: 3177-84.
48. Lindblad M, Lagergren J, Garcia Rodriguez LA. Nonsteroidal antiinflammatory drugs and risk of esophageal and gastric cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2005; 14: 444-50.
49. James MW, Chen CM, Goddard WP, Scott BB, Goddard AF. Risk factors for gastrointestinal malignancy in patients with iron-deficiency anaemia. European journal of gastroenterology & hepatology. 2005; 17: 1197-203.
50. Yang HB, Cheng HC, Sheu BS, Hung KH, Liou MF, Wu JJ. Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication. Alimentary pharmacology & therapeutics. 2007; 25: 455-61.
51. Leung WK, Ng EK, Chan FK, Chan WY, Chan KF, Auyeung AC, et al. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12: 4766-72.
52. Fortuny J, Johnson CC, Bohlke K, Chow WH, Hart G, Kucera G, et al. Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2007; 5: 1154-9 e3.
53. Flossmann E, Rothwell PM, British Doctors Aspirin T, the UKTIAAT. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007; 369: 1603-13.
54. Sadeghi S, Bain CJ, Pandeya N, Webb PM, Green AC, Whiteman DC, et al. Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008; 17: 1169-78.
55. Figueroa JD, Terry MB, Gammon MD, Vaughan TL, Risch HA, Zhang FF, et al. Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer causes & control: CCC. 2009; 20: 361-8.
56. Hoyo C, Schildkraut JM, Murphy SK, Chow WH, Vaughan TL, Risch H, et al. IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas. International journal of cancer Journal international du cancer. 2009; 125: 2673-8.
57. Abnet CC, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a metaanalysis. British journal of cancer. 2009; 100: 551-7.
58. Manas MD, Domper A, Albillos A, Hernandez A, Carpintero P, Lorente R, et al. Endoscopic follow-up of gastric ulcer in a population at intermediate risk for gastric cancer. Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva. 2009; 101: 317-24.
59. Yanaoka K, Oka M, Yoshimura N, Deguchi H, Mukoubayashi C, Enomoto S, et al. Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylorinegative precancerous lesion. International journal of cancer Journal international du cancer. 2010; 126: 1467-73.
60. Gonzalez CA, Pardo ML, Liso JM, Alonso P, Bonet C, Garcia RM, et al. Gastric cancer occurrence in preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. International journal of cancer Journal international du cancer. 2010; 127: 2654-60.
61. Bertuccio P, Bravi F, Bosetti C, Negri E, La Vecchia C. Aspirin and gastric cancer risk. European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation. 2010; 19: 426-7.
62. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011; 377: 31-41.
63. Lee J, Lee SH, Hur KY, Woo SY, Kim SW, Kang WK. Statins and the risk of gastric cancer in diabetes patients. BMC cancer. 2012; 12: 596.
64. Dinarello CA. Anti-inflammatory Agents: Present and Future. Cell. 2010; 140:935-50.
65. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Annals of internal medicine. 2013; 159: 77-85.
66. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011; 378: 2081-7.
67. Gu Q, Wang JD, Xia HH, Lin MC, He H, Zou B, et al. Activation of the caspase-8/Bid and Bax pathways in aspirin-induced apoptosis in gastric cancer. Carcinogenesis. 2005; 26: 541-6.
68. Din FV, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R, et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut. 2010; 59: 1670-9.
69. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and nonvascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012; 379: 1602-12.
70. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Alimentary pharmacology & therapeutics. 2005; 22: 795-801.
71. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer research. 1997; 57: 1276-80.
72. Nam KT, Hahm KB, Oh SY, Yeo M, Han SU, Ahn B, et al. The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10: 8105-13.
73. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase- 2. The New England journal of medicine. 2001; 345: 433-42.
74. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. The New England journal of medicine. 2005; 352: 1071-80.